PATENT CLAIM ANALYSIS

Application Number: 15912103
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "400000"]

Abstract:
Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

Claim (Index 13):
The dosage form of  claim 9 , wherein the leukotriene blocker is Montelukast and the safe and effective amount is 0.5 mg to 20 mg.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 90.0
- Lexical Diversity: 1.75862
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15299054', '15281144', '15588897', '12666491', '11724410']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7252301444205087
- 35 USC 102 Novelty (BERT): 0.5491416526282136
- Combined Prediction Score: 0.7076212952412791
- Mean Citation Score: 226.38314
- Max Citation Score: 415.47818
- Similarity Product: 294.40250761637685

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test